{"title":"Blood miRNAs as Potential Diagnostic Biomarkers for Chronic Obstructive Pulmonary Disease: A Meta-Analysis","authors":"Xiaohua Li, Guoxia Fu, Chunrong Zhang, Yu Wu, Hua Guo, Weiming Li, Xuefeng Zeng","doi":"10.2147/copd.s457172","DOIUrl":null,"url":null,"abstract":"<strong>Purpose:</strong> Investigate the efficacy of blood microRNAs (miRNAs) as diagnostic biomarkers for Chronic Obstructive Pulmonary Disease (COPD).<br/><strong>Patients and Methods:</strong> We conducted a comprehensive search in English and Chinese databases, selecting studies based on predetermined criteria. Diagnostic parameters like summarized sensitivity (SSEN), summarized specificity (SSPE), summarized positive likelihood ratio (SPLR), summarized negative likelihood ratio (SNLR), and diagnostic odds ratio (DOR), and area under the curve (AUC) of the summary receiver operating characteristic (SROC) curves were analyzed using a bivariate model. Each parameter was accompanied by a 95% confidence interval (CI).<br/><strong>Results:</strong> Eighteen high-quality studies were included. For diagnosing COPD with blood miRNAs, the SSEN was 0.83 (95% CI 0.76– 0.89), SSPE 0.76 (95% CI 0.70– 0.82), SPLR 3.50 (95% CI 2.66– 4.60), SNLR 0.22 (95% CI 0.15– 0.33), DOR 15.72 (95% CI 8.58– 28.77), and AUC 0.86 (95% CI 0.82– 0.88). In acute exacerbations, SSEN was 0.85 (95% CI 0.76– 0.91), SSPE 0.80 (95% CI 0.73– 0.86), SPLR 4.26 (95% CI 3.05– 5.95), SNLR 0.19 (95% CI 0.12– 0.30), DOR 22.29 (95% CI 11.47– 43.33), and AUC 0.89 (95% CI 0.86– 0.91).<br/><strong>Conclusion:</strong> Blood miRNAs demonstrate significant accuracy in diagnosing COPD, both in general and during acute exacerbations, suggesting their potential as reliable biomarkers.<br/><br/><strong>Keywords:</strong> miRNAs, chronic obstructive pulmonary disease, biomarker, meta-analysis, diagnosis<br/>","PeriodicalId":13792,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"10 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/copd.s457172","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Investigate the efficacy of blood microRNAs (miRNAs) as diagnostic biomarkers for Chronic Obstructive Pulmonary Disease (COPD). Patients and Methods: We conducted a comprehensive search in English and Chinese databases, selecting studies based on predetermined criteria. Diagnostic parameters like summarized sensitivity (SSEN), summarized specificity (SSPE), summarized positive likelihood ratio (SPLR), summarized negative likelihood ratio (SNLR), and diagnostic odds ratio (DOR), and area under the curve (AUC) of the summary receiver operating characteristic (SROC) curves were analyzed using a bivariate model. Each parameter was accompanied by a 95% confidence interval (CI). Results: Eighteen high-quality studies were included. For diagnosing COPD with blood miRNAs, the SSEN was 0.83 (95% CI 0.76– 0.89), SSPE 0.76 (95% CI 0.70– 0.82), SPLR 3.50 (95% CI 2.66– 4.60), SNLR 0.22 (95% CI 0.15– 0.33), DOR 15.72 (95% CI 8.58– 28.77), and AUC 0.86 (95% CI 0.82– 0.88). In acute exacerbations, SSEN was 0.85 (95% CI 0.76– 0.91), SSPE 0.80 (95% CI 0.73– 0.86), SPLR 4.26 (95% CI 3.05– 5.95), SNLR 0.19 (95% CI 0.12– 0.30), DOR 22.29 (95% CI 11.47– 43.33), and AUC 0.89 (95% CI 0.86– 0.91). Conclusion: Blood miRNAs demonstrate significant accuracy in diagnosing COPD, both in general and during acute exacerbations, suggesting their potential as reliable biomarkers.
期刊介绍:
An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals